Search

Your search keyword '"Sánchez‐Soblechero, Antonio"' showing total 14 results
Start Over Author "Sánchez‐Soblechero, Antonio"
14 results on '"Sánchez‐Soblechero, Antonio"'

1. The profile of refractory chronic cluster headache

Author

Membrilla, Javier A., Cuadrado, María-Luz, González-García, Nuria, Porta-Etessam, Jesús, Sánchez-Soblechero, Antonio, Lozano Ros, Alberto, Gonzalez-Martinez, Alicia, Gago-Veiga, Ana Beatriz, Quintas, Sonia, Rodríguez Vico, Jaime S., Jaimes, Alex, Llorente Ayuso, Lucía, Roa, Javier, Estebas, Carlos, and Díaz-de-Terán, Javier

Published
2024
Full Text
View/download PDF

3. Where Should I Draw the Line: PET-Driven, Data-Driven, or Manufacturer Cut-Off?

Author

Sánchez-Soblechero, Antonio, primary, López-García, Sara, additional, Lage, Carmen, additional, Fernández-Matarrubia, Marta, additional, Irure, Juan, additional, López-Hoyos, Marcos, additional, Jiménez-Bonilla, Julio, additional, Quirce, Remedios, additional, de Arcocha-Torres, María, additional, Cuenca-Vera, Oriana, additional, Martín-Arroyo, Juan, additional, Martínez-Dubarbie, Francisco, additional, Pozueta, Ana, additional, García-Martínez, María, additional, Infante, Jon, additional, Sánchez-Juan, Pascual, additional, and Rodríguez-Rodríguez, Eloy, additional

Published
2024
Full Text
View/download PDF

4. Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti‐calcitonin gene‐related peptide therapies: The PREVENAC study

Author

Gago‐Veiga, Ana Beatriz, primary, Lopez‐Alcaide, Noelia, additional, Quintas, Sonia, additional, Fernández Lázaro, Iris, additional, Casas‐Limón, Javier, additional, Calle, Carlos, additional, Latorre, Germán, additional, González‐García, Nuria, additional, Porta‐Etessam, Jesús, additional, Rodriguez‐Vico, Jaime, additional, Jaimes, Alex, additional, Gómez García, Andrea, additional, García‐Azorín, David, additional, Guerrero‐Peral, Ángel Luis, additional, Sierra, Álvaro, additional, Lozano Ros, Alberto, additional, Sánchez‐Soblechero, Antonio, additional, Díaz‐de‐Teran, Javier, additional, Membrilla, Javier A., additional, Treviño, Cristina, additional, and Gonzalez‐Martinez, Alicia, additional

Published
2024
Full Text
View/download PDF

5. Translating NIA‐AA criteria into usual practice: Report from the ReDeMa Project

Author

Sánchez‐Soblechero, Antonio, primary, Berbel, Angel, additional, Villarejo, Alberto, additional, Palmí‐Cortés, Itziar, additional, Vieira, Alba, additional, Gil‐Moreno, María José, additional, Fernández, Cristina, additional, Martín‐Montes, Ãngel, additional, Carreras, María Teresa, additional, Fernández, Yolanda, additional, Puertas, Carolina, additional, Blanco‐Palmero, Victor, additional, Llamas, Sara, additional, González‐Sánchez, Marta, additional, Lapeña, Teresa, additional, de Luis, Pilar, additional, Manzano, Sagrario, additional, and Olazarán, Javier, additional

Published
2024
Full Text
View/download PDF

6. RE‐START: Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine.

Author

Romero del Rincón, Celia, Gonzalez‐Martinez, Alicia, Quintas, Sonia, García‐Azorín, David, Fernández Lázaro, Iris, Guerrero‐Peral, Angel Luis, Gonzalez Osorio, Yesica, Santos‐Lasaosa, Sonia, González Oria, Carmen, Sánchez Rodríguez, Norberto, Iglesias Díez, Fernando, Echavarría Íñiguez, Ana, Gil Luque, Sendoa, Huerta‐Villanueva, Mariano, Campoy Díaz, Sergio, Muñoz‐Vendrell, Albert, Lozano Ros, Alberto, Sánchez‐Soblechero, Antonio, Velasco Juanes, Fernando, and Kortazar‐Zubizarreta, Izaro

Subjects
PEPTIDES, CALCITONIN gene-related peptide, MIGRAINE, TERMINATION of treatment, MONOCLONAL antibodies
Abstract

Background and purpose: According to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene‐related peptide (anti‐CGRP MAb) may be considered after 12–18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption. Methods: This was a prospective study conducted in 14 Headache Units in Spain. We included patients with response to anti‐CGRP MAb with clinical worsening after withdrawal and resumption of treatment. Numbers of monthly migraine days (MMD) and monthly headache days (MHD) were obtained at four time points: before starting anti‐CGRP MAb (T‐baseline); last month of first treatment period (T‐suspension); month of restart due to worsening (T‐worsening); and 3 months after resumption (T‐reintroduction). The response rate to resumption was calculated. Possible differences among periods were analysed according to MMD and MHD. Results: A total of 360 patients, 82% women, with a median (interquartile range [IQR]) age at migraine onset of 18 (12) years. The median (IQR) MHD at T‐baseline was 20 (13) and MMD was 5 (6); at T‐suspension, the median (IQR) MHD was 5 (6) and MMD was 4 (5); at T‐worsening, the median (IQR) MHD was 16 (13) and MMD was 12 (6); and at T‐reintroduction, the median (IQR) MHD was 8 (8) and MHD was 5 (5). In the second period of treatment, a 50% response rate was achieved by 57.4% of patients in MHD and 65.8% in MMD. Multivariate models showed significant differences in MHD between the third month after reintroduction and last month before suspension of first treatment period (p < 0.001). Conclusion: The results suggest that anti‐CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Neurological complications of COVID‐19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic

Author

Portela‐Sánchez, Sofía, primary, Sánchez‐Soblechero, Antonio, additional, Melgarejo Otalora, Pedro José, additional, Rodríguez López, Ángela, additional, Velilla Alonso, Gabriel, additional, Palacios‐Mendoza, Michael Armando, additional, Cátedra Caramé, Carlos, additional, Amaya Pascasio, Laura, additional, Mas Serrano, Miguel, additional, Massot‐Tarrús, Andreu, additional, De La Casa‐Fages, Beatriz, additional, Díaz‐Otero, Fernando, additional, Catalina, Irene, additional, García Domínguez, Jose Manuel, additional, Pérez‐Sánchez, Javier Ricardo, additional, Muñoz‐Blanco, José Luis, additional, and Grandas, Francisco, additional

Published
2021
Full Text
View/download PDF

8. Acute Stroke Care during the COVID-19 Pandemic: Reduction in the Number of Admissions of Elderly Patients and Increase in Prehospital Delays

Author

Velilla-Alonso, Gabriel, primary, García-Pastor, Andrés, additional, Rodríguez-López, Ángela, additional, Gómez-Roldós, Ana, additional, Sánchez-Soblechero, Antonio, additional, Amaya-Pascasio, Laura, additional, Díaz-Otero, Fernando, additional, Fernández-Bullido, Yolanda, additional, Iglesias-Mohedano, Ana María, additional, Vázquez-Alén, Pilar, additional, Vales-Montero, Marta, additional, and Gil-Núñez, Antonio-Carmelo, additional

Published
2021
Full Text
View/download PDF

12. Plasma exchange in acute attacks of demyelinating diseases of the central nervous system: clinical outcomes and predictors of response

Author

Palacios-Mendoza, Michael A., primary, Martínez Ginés, María L., additional, Melgarejo Otálora, Pedro J., additional, Cuello, Juan P., additional, Sánchez-Soblechero, Antonio, additional, Lozano Ros, Alberto, additional, Aparcero-Suero, José A., additional, López Anguita, Sergio, additional, Anaya, Fernando, additional, and García Domínguez, José M., additional

Published
2020
Full Text
View/download PDF

14. Clinical predictors of therapeutic failure of occipital nerve stimulation in refractory chronic cluster headache.

Author

Membrilla, Javier A, Cuadrado, María-Luz, González-García, Nuria, Porta-Etessam, Jesús, Sánchez-Soblechero, Antonio, Lozano Ros, Alberto, Gonzalez-Martinez, Alicia, Gago-Veiga, Ana Beatriz, Quintas, Sonia, Rodríguez Vico, Jaime S, Jaimes, Alex, Llorente Ayuso, Lucía, Roa, Javier, Estebas, Carlos, and Díaz-de-Terán, Javier

Subjects
*NEURAL stimulation, *CLUSTER headache, *CONDITIONED response, *NERVE block, *DELAYED diagnosis, *MENTAL illness
Abstract

Background: Occipital nerve stimulation (ONS) is a treatment with evidence in refractory chronic cluster headache (CCH). However, the variable response rate and cost make it necessary to investigate predictors of response. Methods: This is a cross-sectional study conducted through the review of medical records of CCH patients from six hospitals in Madrid. Epidemiological and clinical variables were compared between patients with ONS failure and the rest. ONS failure was defined as the need for device withdrawal or switch off because of lack of response or adverse events. Results: From a series of 88 CCH, 26 (29.6%) underwent ONS surgery, of whom 13/26 (50.0%) failed because lack of response. ONS failure group had an earlier headache onset (mean ± SD) of 27.7 ± 6.9 vs. 36.7 ± 11.8 years, p = 0.026) and a higher smoking rate (100% vs. 42.9%, p = 0.006). Stational fluctuations (58.3% vs. 7.7%, p = 0.007) and nocturnal exacerbations (91.7% vs. 53.9%, p = 0.035) were more frequent in the ONS failure group as well. There was no difference between groups in diagnostic delay, years of evolution prior to surgery, mental illness, comorbidity with other headache disorders or chronic pain conditions or prior response to occipital nerves anesthetic blocks. Conclusions: Some clinical features such as an early debut, smoking and seasonal or circadian fluctuations could be related to failure of ONS in refractory CCH. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results